Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$66.00 +1.27 (+1.96%)

Closing price 04/14/2025 03:58 PM Eastern

Extended Trading

$65.59 -0.41 (-0.62%)

As of 08:08 AM Eastern

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
3

Buy
7

Based on 10 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 3 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for NVO.

Consensus Price Target

$145.25
120.08% Upside

According to the 10 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $145.25. The highest price target for NVO is $160.00, while the lowest price target for NVO is $105.00. The average price target represents a forecasted upside of 120.08% from the current price of $66.00.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 4/15/24 to 4/15/25	1 Month Ago 3/16/24 to 3/16/25	3 Months Ago 1/16/24 to 1/15/25	1 Year Ago 4/16/23 to 4/15/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$145.25	$145.25	$140.20	$133.60
Forecasted Upside	120.08% Upside	88.09% Upside	68.94% Upside	7.87% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Remove Ads

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	120.08% Upside	24,967.56% Upside	25.80% Upside
News Sentiment Rating	Positive News See Recent NVO News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/13/2025	Kepler Capital Markets 4 of 5 stars	D. Evans Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/3/2025	Stifel Nicolaus 4 of 5 stars		Downgrade	Buy ➝ Hold
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight
1/8/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Walton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Buy
1/6/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Kapadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
12/23/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$156.00 ➝ $105.00	+23.53%
12/2/2024	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Parkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+49.39%
6/10/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:09 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Recent earnings results showed a strong performance, with Novo Nordisk reporting $0.91 earnings per share, exceeding analysts' expectations of $0.88. This indicates robust financial health and effective management.
The company has a high net margin of 34.81%, suggesting that it retains a significant portion of revenue as profit, which is attractive for investors looking for profitability.
As of the latest trading session, Novo Nordisk's stock price is $62.58, which reflects a significant drop from its 52-week high of $148.15. This could present a buying opportunity for investors looking for undervalued stocks.
Institutional investors hold 11.54% of Novo Nordisk's stock, indicating confidence from large financial entities, which can be a positive signal for retail investors.
The company has a solid return on equity of 84.68%, demonstrating effective use of equity investments to generate profits, which is a key metric for assessing a company's financial performance.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Shares of Novo Nordisk have recently experienced a decline, trading down 6.7% in one session, which may indicate volatility and potential risks for investors.
The company's current ratio is 0.74, which is below 1.0, suggesting that it may not have enough short-term assets to cover its short-term liabilities, raising concerns about liquidity.
With a debt-to-equity ratio of 0.62, while not excessively high, it indicates that the company is using some leverage, which can increase financial risk, especially in uncertain market conditions.
Recent trading volumes have shown fluctuations, with 10,847,371 shares traded compared to an average of 5,643,894, which may suggest instability in investor confidence.
The stock's beta of 0.61 indicates lower volatility compared to the market, but it also means that the stock may not perform as well in a rising market, potentially limiting upside for investors.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $145.25, with a high forecast of $160.00 and a low forecast of $105.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 120.08% based on their 12-month stock forecasts.
: Over the previous 90 days, Novo Nordisk A/S's stock had 1 upgrade and 1 downgrade by analysts.
: Novo Nordisk A/S has been rated by research analysts at Kepler Capital Markets, Morgan Stanley, and Stifel Nicolaus in the past 90 days.
: Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:NVO) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target